logo
Better EV Stock: QuantumScape vs. ChargePoint

Better EV Stock: QuantumScape vs. ChargePoint

Yahoo25-05-2025

QuantumScape still hasn't sold any of its solid-state batteries yet.
ChargePoint will install more charging stations as the EV market warms up again.
Investors should stick with the company that is generating actual revenues.
10 stocks we like better than QuantumScape ›
QuantumScape (NYSE: QS) and ChargePoint (NYSE: CHPT) represent two different ways to invest in the growing electric vehicle (EV) market.
QuantumScape develops solid-state lithium metal batteries which provide better thermal resistance, faster charging times, and higher maximum capacities than traditional lithium ion batteries. ChargePoint is the largest builder of residential and commercial EV charging stations in North America and Europe.
QuantumScape and ChargePoint both closed at their record highs during the apex of the meme stock mania in December 2020. But today, they're both trading more than 95% below their all-time highs. Let's see why these two EV stocks ran out of juice -- and if they're worth buying now.
QuantumScape has been developing its solid-state batteries for the past 15 years, but it still hasn't commercialized any of its products. Its first battery, the QSE-5, should have an energy density of over 800 Wh/L (watt hours per liter) and can be rapidly charged from 10% to 80% in less than 15 minutes. Most traditional lithium ion EV batteries have an average density of 300-700 Wh/L with an average fast charging time of 20 minutes to an hour.
QuantumScape has been working with Volkswagen for more than a decade to develop and test those batteries, but it's only shipped some low volume test samples so far. It doesn't expect to start mass-producing or commercializing its first batteries until 2026.
For 2025, ChargePoint expects to ship more low volume test samples as it transitions from its current Raptor separator process to the newer Cobra separator process. It expects that sweeping upgrade -- which should boost its yields, equipment productivity, and cell reliability -- to pave the way toward the commercialization of its batteries.
However, QuantumScape still faces a lot of competition from major automakers, including Toyota and Nio, which are developing their own solid-state batteries. Other start-ups like Blue Solutions and Solid Power are also rushing toward the same goal.
Without any revenue, QuantumScape is a tough stock to value. However, analysts expect its revenue to rise to $4 million in 2026 and $93 million in 2027 as it commercializes its first batteries. With an enterprise value of $1.63 billion, it might not seem cheap at 18 times its 2027 sales -- but its revenue could skyrocket over the following years if it successfully scales up its business.
At the end of fiscal 2025 (which ended this January), ChargePoint was managing 342,000 charging ports across North America and Europe. More than 33,000 of those ports were Level 3 fast chargers, while the rest were slower Level 2 chargers.
ChargePoint mainly sells its connected charging stations to businesses that want to set their own prices. It provides those customers with network access, billing, and customer support services. Those advantages set it apart from Tesla's Superchargers, which operate as stand-alone stalls and extensions of the automaker's own digital ecosystem.
Therefore, Tesla, which operates more than 67,000 Superchargers worldwide, shouldn't be considered a direct competitor to ChargePoint. Instead, ChargePoint's closest competitor is EVgo, which operates a smaller domestic network of 4,240 charging stalls.
ChargePoint's revenue surged 65% in fiscal 2022 and 93% in fiscal 2023 as the EV market expanded, but it only grew 8% in fiscal 2024 and dropped 18% in fiscal 2025.
That slowdown was caused by rising interest rates, which chilled the EV market and discouraged its commercial and residential customers from installing new charging stalls. But in fiscal 2025, it significantly narrowed its net loss as it trimmed its workforce and rolled out a new dynamic pricing model that grants its station owners even more control over their pricing variables.
From fiscal 2025 to fiscal 2028, analysts expect ChargePoint's revenue to grow at a compound annual growth rate of 21% to $738 million as interest rates decline and the EV market stabilizes. They also expect its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to turn positive in fiscal 2027 and surge to $80 million in fiscal 2028.
With an enterprise value of $495 million, ChargePoint trades at just 1.1 times this year's sales. It could command a much higher valuation once the EV market warms up again.
QuantumScape's stock might soar once it starts selling its first batteries, but its stock could easily sink lower until that happens. So for now, I'd rather buy ChargePoint as an undervalued play on the EV market instead of putting too much faith in QuantumScape's ambitious long-term plans.
Before you buy stock in QuantumScape, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and QuantumScape wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!*
Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends Volkswagen Ag. The Motley Fool has a disclosure policy.
Better EV Stock: QuantumScape vs. ChargePoint was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Corbin Burnes needs Tommy John surgery. Prepare for aftershocks.
Corbin Burnes needs Tommy John surgery. Prepare for aftershocks.

Washington Post

time27 minutes ago

  • Washington Post

Corbin Burnes needs Tommy John surgery. Prepare for aftershocks.

When Arizona Diamondbacks ace Corbin Burnes left a pitch up to CJ Abrams last Sunday and immediately motioned for trainers, everyone at Chase Field understood what it might mean. And when cameras caught Burnes appearing to express concern about his elbow, there was little reason to doubt his self-diagnosis. Burnes has been one of the game's most durable starters since the start of the 2021 season. He knew this would change that. Diamondbacks Manager Torey Lovullo on Friday confirmed what Burnes and others had already suspected: The ace to whom Arizona committed $210 million over the next six years will miss the rest of the 2025 season and most of 2026 because he needs Tommy John surgery. Burnes, 30, will have the procedure next week. All injuries spur ripples — sometimes through a team's active roster, sometimes deep into an organization's minor league depth. But an injury to Burnes, one of the game's preeminent starting pitchers anchoring the rotation of a would-be playoff team fighting for its life, will have aftershocks near and far. The first jolt, of course, will be felt in the desert, where the Diamondbacks are hovering around .500 while trying to steady a pitching staff that was disappointing even with Burnes. Their other ace, Zac Gallen, has been uncharacteristically mediocre. Promising righty Brandon Pfaadt has been getting pummeled and lefty Eduardo Rodriguez only returned from injury Friday, meaning the Diamondbacks cannot be sure what he will give them. As such, if they intend to contend, they will likely need to add a starter at or before the trade deadline. Demand was already high, and with several teams still weighing their commitment to 2025, supply remains limited. But the Burnes injury could also change more than just the Diamondbacks' 2025 calculus; Arizona's owner, Ken Kendrick, has invested in winning recently but could seize the whiff of mediocrity to balance his recently bloated budget. If the Diamondbacks fall out of contention — and without Burnes, the chances of that increase — they could seek trades for first baseman Josh Naylor (making $10.9 million this year), third baseman Eugenio Suarez ($15 million), Gallen ($13.5 million) and right-hander Merrill Kelly ($7 million), all of whom would represent significant savings even with just the post-deadline portions of their salaries gone. Any savings could be crucial, because Burnes's injury also complicates Arizona's offseason. Gallen will be a free agent for the first time, and he will almost certainly want to test the market. Kelly will be a free agent, too. So is Jordan Montgomery, who also underwent Tommy John surgery this year. That leaves Arizona with only three sure things in next year's rotation: Rodriguez, Pfaadt and Ryne Nelson, who was in Arizona's bullpen but has started three games for the Diamondbacks this year. They will need more to contend in the National League West, which means they might need to be major players in this year's offseason starting pitching market, even though they just gave Burnes the largest pitching contract in their history. Fortunately for anyone seeking starting pitching this winter, options abound. Gallen, Framber Valdez and Dylan Cease headline a class that will also include Ranger Suárez, Chris Bassitt and Zach Eflin, not to mention the dozen or so strong starters who could opt out of deals if they so choose. But one more team on the prowl increases demand this winter — just like one more seller changes the entire trade deadline a few months earlier. For that reason, the aftershocks of the Burnes injury will also be felt in New York and Los Angeles and Chicago and beyond. If the Diamondbacks do decide to sell, even an underperforming Gallen would be one of the more coveted assets available — a potential fate-alterer for any postseason team. Suarez, too, offers the kind of clubhouse pep and on-field power that would make him a highly sought after deadline option. The Yankees, for example, have been hunting for a third base solution all year. Naylor has plenty of pop and postseason experience, too. Kelly has proven himself to be as tough as they come. If the Diamondbacks sell, any one of those players could change a team's October trajectory, if the stars align. Arizona is currently one of several teams that expected to contend and are underachieving. The Boston Red Sox, Atlanta Braves, Baltimore Orioles and Texas Rangers are all hoping to stave off a deadline sale by rejuvenating their chances over the next two months. The more that do so, the higher demand for Arizona's assets will be. The Diamondbacks have not been ones to cave in recent years, in large part because few teams know better how quickly fates can change. In 2023, they found themselves two games under .500 on August 11. They ended up in the World Series. But rallies like those are hard to engineer even with an annual Cy Young contender in the rotation. Without one … well, the contending vultures are starting to gather in the desert.

Has Warren Buffett made his best move ever selling his Apple stock?
Has Warren Buffett made his best move ever selling his Apple stock?

Yahoo

time28 minutes ago

  • Yahoo

Has Warren Buffett made his best move ever selling his Apple stock?

It's never a good idea trying to second-guess the Oracle of Omaha. Warren Buffett sold a huge chunk of his Apple (NASDAQ:AAPL) stock last year. It wasn't the first time he trimmed his position in the tech giant. Back in 2021, he admitted selling was 'probably a mistake'. But, amid recent share price weakness, I doubt he will repeat the same line this time. Recent soundings from Apple CEO Tim Cook seem to indicate he has taken a leaf out of Buffett's playbook. In a recent earnings call, he pushed investors to be patient as it attempts to roll out AI features in the iPhone. 'Not first, but best' was how he put it in an interview last year. In an investing landscape measured in quarterly earnings, though, many don't have much patience. In some respects, he is right. Three years into the generative AI revolution and not one consumer product has emerged, other than ChatGPT, of course. And that's despite the industry spending hundreds of billions of dollars, and with the might of the media hyping the technology on an almost daily basis. Recently, Jony Ive, the architect instrumental in the design of the iPhone, sold his company to OpenAI for $6.5bn. At the not-for-profit startup, he is working on what has been described as a 'screen-free' device. Some reports highlight that mass production could start as early as 2027. The threat is clearly on Apple's radar. During the ongoing Google anti-trust trial, one of Apple's senior executive stated: 'You may not need an iPhone 10 years from now, as crazy as that sounds.' Given the present state of hardware technology and the extremely vague statements that have come from Sam Altman regarding no-screen devices, I'm not willing to give much credence to these remarks. But, of course, that could change in the years ahead. Apple has a history of not rushing into a new technology, until its full potential is understood. It was a little-known company when General Magic invented the first smartphone. It didn't invent the music player, either. The biggest short-term risk to the stock is tariffs. Apple has undoubtedly been the biggest beneficiary of outsourcing manufacturing to China. It has certainly been a major contributor in pushing the valuation to $3trn. Trump's ambition of seeing the iPhone mass produced in the US is unlikely to ever happen, in my opinion. With consumers being squeezed from all directions these days, I don't believe they would ever stomach paying up to $3,000 for one. Tim Cook has already guided to expect $900m in additional costs over the next quarter. A tiny figure, yes, but I can't see it ending there. Without price increases, the frothy valuation looks unsustainable. As I just said, I'm not sure that consumers will be as obliging as in the past and accept such increases. As for Buffett, he still holds a significant chunk of Apple stock. But with a trailing price-to-earnings of 32, I'm not sure the risks are fully priced in. Therefore, I won't be investing. The post Has Warren Buffett made his best move ever selling his Apple stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Andrew Mackie has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store